131030 — Optus Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapContrarian

Annual income statement for Optus Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	60,827	57,316	58,658	72,426	81,905
Cost of Revenue
Gross Profit	38,324	32,525	31,707	41,429	44,714
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	45,319	46,845	53,399	64,240	73,317
Operating Profit	15,508	10,472	5,258	8,187	8,588
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	18,502	10,479	6,828	12,970	12,084
Provision for Income Taxes
Net Income After Taxes	14,405	9,892	5,012	10,760	10,308
Net Income Before Extraordinary Items
Net Income	14,405	9,892	5,012	10,760	10,308
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	14,405	9,892	5,012	10,760	10,308
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	893	616	279	692	675
Dividends per Share